This clinical trial is designed for men and women who have multiple myeloma (MM) or diffuse large B-cell lymphoma (DLBCL) that has recurred after previous treatment or has not responded to their last treatment.
The purpose of this study is to evaluate the safety and effectiveness of the study drug EZM0414 at various dosages.
EZM0414 is an experimental drug that has not yet been approved by the United States Food and Drug Administration (FDA) for this type of cancer.
EZM0414 targets and can stop certain cancer cell growth by stopping a protein called SETD2, a histone lysine methyltransferase, from working.
In this study participants will take EZM0414 once a day on an empty stomach (no food 2 hours prior and 1 hour after) at approximately the same time each day in doses determined by the study team.
The study also involves collection of samples, such as y blood, bone marrow (biopsy and aspirates), tissue, and urine.
Participation is expected to last around 3 years.
Detailed eligibility reviewed when participant contacts the study team.